Publications by authors named "T Riehl"
Background: Discoveries of new species often depend on one or a few specimens, leading to delays as researchers wait for additional context, sometimes for decades. There is currently little professional incentive for a single expert to publish a stand-alone species description. Additionally, while many journals accept taxonomic descriptions, even specialist journals expect insights beyond the descriptive work itself.
View Article and Find Full Text PDFArticle Synopsis
- The family Acanthaspidiidae Menzies, 1962, is a type of marine isopod found worldwide, primarily in deep waters and mostly in the Southern Hemisphere, with 36 species identified across three genera.
- A new species from Maltese waters has been discovered, marking the first record of this family in the Mediterranean Sea and expanding the genus by one species.
- The new species has distinctive features such as a large pre-ocular spine and specific shapes in its body parts, accompanied by an identification key for related species and revisions to genus descriptions.
Article Synopsis
- Modern sciences are becoming more complex and specialized, leading to collaborative publications but a lag in collaboration within integrative taxonomy, despite attempts to accelerate the process.
- The Senckenberg Ocean Species Alliance is creating a taxonomic service to provide essential data for describing new species and to connect a global network of taxonomists.
- There is an urgent need for faster taxonomic descriptions due to biodiversity loss in the Anthropocene, as the current pace is inadequate and the field is often seen as outdated.
Apolipoprotein M (ApoM) binds sphingosine-1-phosphate (S1P) and is inversely associated with mortality in human heart failure (HF). Here, we show that anthracyclines such as doxorubicin (Dox) reduce circulating ApoM in mice and humans, that ApoM is inversely associated with mortality in patients with anthracycline-induced heart failure, and ApoM heterozygosity in mice increases Dox-induced mortality. In the setting of Dox stress, our studies suggest ApoM can help sustain myocardial autophagic flux in a post-transcriptional manner, attenuate Dox cardiotoxicity, and prevent lysosomal injury.
View Article and Find Full Text PDFTumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)-an open-label, global, multicohort trial-evaluated the safety and efficacy of first-line targeted therapies or immunotherapy in patients with unresectable Stage IIIB or IV advanced or metastatic non-small cell lung cancer who were selected for biomarker status using blood-based targeted next-generation sequencing. In the Phase 3 cohort C evaluating blood-based (b)TMB as a biomarker of atezolizumab efficacy, patients with bTMB of ≥10 (N = 471) were randomized 1:1 to receive atezolizumab or platinum-based chemotherapy per local standard of care.
View Article and Find Full Text PDF